Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$8.16 - $22.89 $247,680 - $694,780
-30,353 Reduced 51.38%
28,723 $249,000
Q1 2024

May 15, 2024

BUY
$19.93 - $29.71 $693,723 - $1.03 Million
34,808 Added 143.43%
59,076 $1.22 Million
Q4 2023

Feb 14, 2024

BUY
$5.71 - $24.13 $51,047 - $215,722
8,940 Added 58.32%
24,268 $560,000
Q3 2023

Nov 14, 2023

BUY
$7.99 - $15.36 $122,470 - $235,438
15,328 New
15,328 $122,000
Q2 2022

Aug 15, 2022

BUY
$7.25 - $12.71 $2,044 - $3,584
282 Added 2.07%
13,921 $110,000
Q1 2022

May 16, 2022

SELL
$8.67 - $14.11 $10,499 - $17,087
-1,211 Reduced 8.15%
13,639 $166,000
Q4 2021

Feb 14, 2022

BUY
$10.18 - $18.4 $151,173 - $273,240
14,850 New
14,850 $182,000

Others Institutions Holding EYPT

About EyePoint Pharmaceuticals, Inc.


  • Ticker EYPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,072,200
  • Market Cap $214M
  • Description
  • EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...
More about EYPT
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.